四氯化碳诱导的小鼠肝纤维化模型中SDF-1/αCXCR4的表达及其意义

目的检测四氯化碳（CCl4）诱导的肝纤维化小鼠模型肝脏SDF-1/αCXCR4的表达,评价SDF-1/αCXCR4轴与肝纤维化的关系,为研究肝纤维化肝损伤发生及损伤修复机制研究提供基础。方法选用6周龄雌性纯系C57小鼠,采用40%的CCl4/橄榄油溶液腹腔注射,剂量为1 mL/kg,每周2次,共4周,制成肝纤维化模型,取肝纤维化及正常对照组小鼠肝脏标本,采用RT-PCR及免疫组化检测SDF-1α的表达,采用RT-PCR及Western检测CXCR4受体的表达。结果与对照组相比,SDF-1α及CXCR4在肝纤维化模型小鼠肝脏组织中的表达较对照组明显上调,差异具有统计学意义（P〈0.05）。结论肝纤维小鼠肝组织的SDF-1/αCXCR4受体表达上调,为研究肝纤维化肝损伤机制及干细胞移植治疗提供理论基础。     

SIRT6 对肝细胞脂质合成的影响及其转录基因分析

目的:在肝脏L-02 SIRT6-KO细胞系中,观察SIRT6在肝脏脂滴形成中的作用,初步研究在肝脏脂质代谢中SIRT6相关的转录差异基因发挥作用的分子机制。方法:利用基因敲除技术TALEN技术,构建肝脏L-02 SIRT6特异性敲除细胞系,并经q PCR和Western blot检测其表达水平;利用油酸刺激L-02 SIRT6-KO细胞及其对照组,体外模拟肝脏脂肪变的条件,并经高内涵和油红染色验证其脂滴形成能力;利用基因芯片检测L-02 SIRT6-KO及其对照细胞系中相关差异基因,并经生物信息学分析筛选脂代谢相关差异基因。结果:建立人肝脏SIRT6特异性敲除细胞系,q PCR显示m RNA下降50%,但Western blot证明SIRT6完全敲除;BODIPY实验及油红O染色发现,L-02 SIRT6-KO细胞比对照组其脂滴形成数量增多,高内涵荧光检测显示L-02 SIRT6-KO细胞中脂滴荧光强度比对照组增强(176.38±2.55 vs 104.26±2.08);通过对差异转录基因分析,发现了一组在脂质代谢中和SIRT6相关的关键基因如STEAP4、HMGA2、PDE1A、INSL4等。结论:成功建立人肝脏L-02 SIRT6-KO细胞系,并经实验证明SIRT6缺失能够促进脂滴形成;筛选到一组和SIRT6相关参与脂质代谢的关键基因。     

活化的肝星状细胞RBP-J可诱导性基因敲除小鼠的构建及应用

目的:利用Cre-loxp可诱导系统构建活化的肝星状细胞RBP-J可诱导性基因敲除小鼠模型,以实现肝纤维化过程中活化的肝星状细胞Notch信号通路的特异性阻断。方法:将Sm22αCre ERT2和RBP-Jflox/flox转基因小鼠杂交,得到F1小鼠,将繁殖的F1小鼠继续进行交配,得到F2小鼠,通过PCR鉴定出基因型为Sm22αCre ERT2,RBP-Jflox/flox的小鼠。通过腹腔注射四氯化碳建立肝纤维化模型,检测四氯化碳注射不同时间段后肝脏纤维化进展情况和肝星状细胞活化过程中Sm22α的表达情况。注射他莫昔芬诱导活化肝星状细胞中RBP-J基因的特异性敲除。分选肝星状细胞,q-PCR和Western Blot检测活化肝星状细胞中Notch下游靶基因Hes1、Hey1表达情况以验证敲除效果。结果:通过连续交配我们获得了Sm22αCre ERT2,RBP-Jflox/flox小鼠。四氯化碳腹腔注射4周即可诱导肝脏发生较为明显的纤维化,同时肝星状细胞活化并逐渐高表达Sm22α。给予他莫昔芬诱导Cre重组酶发挥作用后,敲除了活化的肝星状细胞中的RBP-J基因,其下游基因Hes1、Hey1表达降低70%以上,阻断了Notch信号通路。结论:我们成功构建了RBP-J可诱导性条件性基因敲除小鼠模型,实现了小鼠肝纤维化过程中活化肝星状细胞Notch信号通路的阻断,为深入研究Notch信号通路在肝纤维化中的作用和机制奠定了坚实的基础。     

突变型人HGF(tvNK1)对CCl_4诱导的大鼠肝纤维化的影响

目的:探讨突变型人肝细胞生长因子(HGF~(K132E,R134E),tvNK1)对四氯化碳(CCl_4)诱导的SD大鼠肝纤维化的影响。方法:生物发酵大量制备tvNK1,并经腹腔注射于CCl_4诱导的纤维化SD大鼠体内,6周后取肝脏组织,通过real-time PCR和Western blot检测tvNK1对纤维化SD大鼠肝脏中I型胶原蛋白(Collagen type I,Col1A1)、IV型胶原蛋白(Collagen type IV,Col4A1)和α-平滑肌肌动蛋白(α-smooth muscle actin,α-SMA)在mRNA和蛋白水平表达的影响,并进一步通过HE和Masson染色观察tvNK1对纤维化SD大鼠肝脏形态和肝组织胶原纤维的影响。结果:SDSPAGE检测结果显示,获得纯度≥95%的tvNK1。Real-time PCR和Western blot结果显示,tvNK1降低纤维化大鼠肝脏中Col1A1、Col4A1和α-SMA在mRNA和蛋白水平上的表达。HE和Masson染色结果显示,tvNK1减缓纤维化大鼠肝结构的病理性改变,并降低肝脏中胶原纤维含量。结论:tvNK1能抑制CCl_4诱导的大鼠肝纤维化,为预防肝纤维化和其他器官纤维化疾病提供实验依据。     

正丁酸钠通过抑制高迁移率族蛋白B1的表达与释放减轻刀豆蛋白A诱导的小鼠急性肝损伤

本文旨在研究正丁酸钠预处理对刀豆蛋白A(concanavalin A,Con A)诱导的小鼠急性肝损伤的保护作用及机制。给小鼠腹腔注射正丁酸钠(500 mg/kg)0.5 h后,尾静脉注射Con A(15 mg/kg)诱导小鼠急性肝损伤模型,测定小鼠血清谷丙转氨酶(alanine aminotransferase,ALT)、谷草转氨酶(aspartate aminotransferase,AST)的水平;HE染色观察病理学改变;ELISA法检测血清肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、干扰素-γ(interferon-γ,IFN-γ)和高迁移率族蛋白B1(high-mobility group box 1,HMGB1)水平;RT-PCR和免疫组化法检测小鼠肝组织HMBG1的表达与释放。结果显示,正丁酸钠预处理能明显降低Con A诱导的急性肝损伤小鼠血清中ALT和AST水平(P0.01);显著改善肝组织损伤程度;明显降低血清中TNF-α和IFN-γ的水平(P0.01);显著抑制肝组织HMGB1的表达与释放(P0.05或P0.01)。以上结果提示,正丁酸钠预处理对Con A所诱导的小鼠急性肝损伤具有保护作用,可能与其减少炎性细胞因子TNF-α和IFN-γ的产生及抑制HMGB1的表达与释放有关。     

黔产毛蒟水提物对急性肝损伤小鼠的保护作用

探讨黔产毛蒟水提物(PTE)对四氯化碳(CCl_4)诱导小鼠急性肝损伤的保护作用及其作用机制。本研究中将50只昆明种小鼠随机分为5组,各组10只,分别为空白组、模型组(0.01 g/kg的0.15%CCl_4菜油溶液造模)、PTE组(低剂量组0.5 g/kg和高剂量组1.0 g/kg)和阳性对照组(联苯双酯0.15 g/kg)。检测各组小鼠谷丙转氨酶(ALT)、谷草转氨酶(AST)、肿瘤坏死因子(TNF-α)含量;测定肝组织匀浆中脂质过氧化产物丙二醛(MDA)含量及超氧化物歧化酶(SOD)活性;计算肝脏的湿重指数;HE染色法观察肝脏组织的病理学变化。与空白对照组相比,模型组血清ALT、血清AST、肝脏指数、肝组织MDA含量以及血清TNF-α明显增高(均P0.01),肝组织SOD活性明显降低(P0.01),肝组织病理损伤明显。与模型组相比,PTE高剂量组和阳性对照组血清ALT显著降低(P0.01),PTE低、高剂量组和阳性对照组血清AST、肝脏指数、肝组织MDA含量以及血清TNF-α含量均明显降低(P0.05或P0.01),肝组织SOD活性明显升高(P0.01),并减轻了肝组织病理损害。PTE可减轻CCl_4诱导的急性肝损伤,其机制可能与抗氧化、抑制TNF-α的产生有关。     

基于转录组测序探究ATP7B基因缺陷小鼠铜累积诱导肝细胞自噬的相关机制*

目的：分析ATP7B基因缺陷(Wilson's disease,WD)小鼠肝脏组织中自噬相关基因的表达和自噬相关蛋白的相互作用方式,探讨铜累积诱导肝内自噬活化的可能机制。方法：对4周龄和12周龄WD小鼠肝组织进行铜含量检测和转录组测序,对差异基因进行GO和KEGG富集分析,筛选自噬相关差异基因做qRT-PCR和Western blot验证,采用GeneMANIA数据库构建自噬相关差异蛋白的互作网络(PPI)并进行功能注释分析,抑制自噬相关蛋白的表达分析其对自噬的影响。结果：与野生型小鼠相比,WD小鼠肝铜含量显著升高,铜累积导致基因表达模式改变;基于GO数据库统计自噬相关差异基因数目,4周龄和12周龄分别有8个、51个,基于KEGG数据库统计,4周龄和12周龄分别有5个、19个;筛选Ulk1、Ddit4、Plk3等9个基因进行qRT-PCR,定量结果与测序结果表达趋势基本一致;其编码的蛋白质通过共表达、共定位等方式互相作用;Western blot结果显示铜累积导致Ulk1、Plk3、Park2蛋白表达显著增加和细胞自噬发生,抑制Ulk1、Plk3、Park2的蛋白质表达可显著下调细胞自噬水平。结论：WD不同阶段的铜累积可调节肝脏多个自噬相关基因的表达,通过其编码的自噬相关蛋白的互相作用共同诱导肝脏自噬活化以缓解肝损伤。     

红景天苷干预小鼠肝纤维化的研究

目的:以药物诱导的小鼠肝纤维化为实验模型,研究中药红景天苷对该模型是否有治疗作用,及可能的作用方式,结合该药对大鼠肝纤维化的治疗作用,为临床应用该药提供指导.方法:选取10对同窝同性别8周龄小鼠,每对内两只小鼠随机分进实验组(experimental group,EG)与对照组(control group,CG).进行CCl4腹腔注射诱导小鼠肝纤维化,并在诱导中期实验组加入红景天苷,对照组继续原诱导方案.诱导12周结束后取小鼠肝组织进行H&E染色、MASSON染色、巨噬细胞的免疫荧光染色及血清Hyp含量表达测定.结果:实验组小鼠肝组织形态较好,假小叶形成较少,胶原沉积也相对较少(P＜0.001),其血清中的Hyp含量低于对照组(P＜0.01),以上差异有统计学意义.在实验组小鼠肝脏中,F4-80标记的巨噬细胞百分比明显低于对照组(P＜0.001),该差异有统计学意义.结论:红景天苷能够影响小鼠的正常肝纤维化进程,该药减轻了小鼠的肝纤维化程度,对小鼠肝纤维化进程有一定的保护作用.此作用的发挥可能是该药物影响了肝脏中的Kupffer细胞的增殖或者凋亡,从而使得该细胞对炎性信号调控发生变化,使得肝星形细胞分泌胶原减少得以实现.该药在大鼠及小鼠肝纤维化模型上的治疗作用提示其临床应用前景较好.     

姜黄提取物对小鼠肝纤维化的影响

目的:探究姜黄提取物对小鼠肝纤维化的影响。方法:通过CCl4诱导建立肝纤维化小鼠模型,经过姜黄提取物和姜黄素给药干预后,测定并比较每组小鼠血清中谷丙转氨酶(ALT)、谷草转氨酶(AST)、甘油三酯(TG)、总胆固醇(TC)、α肿瘤坏死因子(TNF-α)、白细胞介素6(IL-6)的水平和肝脏中TC、TG、超氧化物歧化酶(SOD)、丙二醛(MDA)、谷胱甘肽过氧化物酶(GSH-Px)的水平。结果:与模型组相比,经姜黄提取物给药干预后,小鼠血清中ALT(P0.01)、AST(P0.05)、TNF-α(P0.05)、IL-6(P0.05)有显著差异,而TG及TC无显著差异;经姜黄素给药干预后,血清中ALT(P0.01)、AST(P0.01)、TG(P0.05)、TNF-α(P0.05)、IL-6(P0.05)有显著差异,而TC无显著差异。与模型组相比,姜黄提取物及姜黄素给药的小鼠肝脏组织中的TG、TC、SOD、MDA和GSH-Px均无显著差异。与姜黄素给药组相比,经姜黄提取物给药干预后,小鼠血清及肝脏中的各项生化指标均无显著差异。病理切片分析观察结果表明,与模型组相比,姜黄提取物给药组及姜黄素给药组小鼠的胶原纤维沉积显著减少,2组间无显著差异。结论:姜黄素提取物对CCl4诱导的小鼠肝纤维化有一定的改善作用,且与姜黄素的效果相当。     

Sirtuin3 deficiency exacerbates carbon tetrachloride−induced hepatic injury in mice

Sirtuin3 (SIRT3) plays an important role in maintaining normal mitochondrial function and alleviating oxidative stress. After carbon tetrachloride (CCl₄) administration, the expression of SIRT3 decreased in the liver of mice, which indicated that the SIRT3 might play a crucial role during chemical‐induced acute hepatic injury. To verify the hypothesis, CCl ₄ was given to induce acute hepatic injury in SIRT3 knockout (KO) mice and wild‐type (WT) mice. CCl ₄‐induced liver injury was more severe in SIRT3 KO mice compared with the WT mice. In addition, the oxidative stress induced by CCl ₄ was enhanced in the SIRT3 KO mice. Furthermore, the increased expression of dynamin‐related protein 1 was also aggravated in SIRT3 KO mice after CCl ₄ administration. In conclusion, our study demonstrated that SIRT3 deficiency exacerbated CCl ₄‐induced impairment of the liver in mice, and the mechanism might be related to enhanced oxidative stress.     

Age-dependent loss of hepatic SIRT1 enhances NLRP3 inflammasome signaling and impairs capacity for liver fibrosis resolution

Our studies indicate that the longevity factor SIRT1 is implicated in metabolic disease; however, whether and how hepatocyte-specific SIRT1 signaling is involved in liver fibrosis remains undefined. We characterized a functional link of age-mediated defects in SIRT1 to the NLRP3 inflammasome during age-related liver fibrosis. In multiple experimental murine models of liver fibrosis, we compared the development of liver fibrosis in young and old mice, as well as in liver-specific SIRT1 knockout (SIRT1 LKO) mice and wild-type (WT) mice. Liver injury, fibrosis, and inflammation were assessed histologically and quantified by real-time PCR analysis. In a model of hepatotoxin-induced liver fibrosis, old mice displayed more severe and persistent liver fibrosis than young mice during liver injury and after injury cessation, as characterized by inhibition of SIRT1, induction of NLRP3, infiltration of macrophages and neutrophils, activation of hepatic stellate cells (HSCs), and excessive deposition and remodeling of the extracellular matrix. Mechanistically, deletion of SIRT1 in hepatocytes resulted in NLRP3 and IL-1β induction, pro-inflammatory response, and severe liver fibrosis in young mice, mimicking the ability of aging to impair the resolution of established fibrosis. In an aging mouse model, chronic-plus-binge alcohol feeding-induced liver fibrosis was attenuated by treatment with MCC950, a selective NLRP3 inhibitor. NLRP3 inhibition ameliorated alcoholic liver fibrosis in old mice by repressing inflammation and reducing hepatocyte-derived danger signaling—ASK1 and HMGB1. In conclusion, age-dependent SIRT1 defects lead to NLRP3 activation and inflammation, which in turn impairs the capacity to resolve fibrosis during aging.     

Lack of tumor necrosis factor receptor type 1 inhibits liver fibrosis induced by carbon tetrachloride in mice

Chronic liver injury causes liver regeneration, resulting in fibrosis. The proinflammatory cytokine tumor necrosis factor (TNF) is involved in the pathogenesis of many acute and chronic liver diseases. TNF has pleiotropic functions, but its role in liver fibrosis has not been clarified. Chronic repeated injection of CCl4 induces liver fibrosis in mice. We examined whether signaling through TNF receptors was critical for this process, using mice lacking either TNF receptor (TNFR) type 1 or TNFR type 2 to define the pathophysiologic role of TNFR signals in liver fibrosis. Liver fibrosis caused by chronic CCl4 exposure was TNF-dependent; histological fibrosis was seen in wild-type (WT) and TNFR-2 knockout (KO) mice, but not in TNFR-1 KO mice. Furthermore, a marked reduction in procollagen and TGF-beta synthesis was observed in TNFR-1 KO mice, which also had little detectable NF-kappa B, STAT3, and AP1 binding, and reduced levels of liver interleukin-6 (IL-6) mRNA compared to WT and TNFR-2 KO mice. In conclusion, our results indicate the possibility that NF-kappa B, STAT3, and AP1 binding by signals transduced through TNFR-1 plays an important role in liver fibrosis formation.     

Inhibition of activated factor X; a new pathway in ameliorating carbon tetrachloride–induced liver fibrosis in rats

Activated factor X has a central role in the coagulation activation and also contributes to chronic inflammation and tissue fibrosis. In this study, rivaroxaban, a direct factor X inhibitor, attenuates liver fibrosis induced by carbon tetrachloride (CCl₄). Male rats were randomly allocated into three groups: a control group, CCl ₄ fibrotic group, and CCl ₄+rivaroxaban (5 mg/kg) group. Liver fibrosis was induced by subcutaneous injection of CCl ₄ twice a week for 6 weeks. Rivaroxaban significantly restored the biochemical parameter including inflammatory and fibrosis markers with histopathological evidence using routine and Masson trichrome staining. It reduced also the expression of tissue factor, fibrin, transforming growth factor and α‐smooth muscle actin in the liver tissues. This concludes that rivaroxaban attenuates liver injury caused by CCl ₄, at least in part by inhibiting coagulation and proinflammatory activation. In conclusion, rivaroxaban may be used for the management of liver fibrosis.     

人脐带间充质干细胞对CCl4诱导肝纤维化的治疗作用研究

目的：探讨人脐带间充质干细胞（UC-MSC）治疗肝纤维化的可行性。方法：采用CCL腹腔注射小鼠制备肝纤维化模型,分别于第4、10周给予尾静脉注射移植UC-MSC进行治疗,检测治疗后血清学指标的改变和病理变化,观察UC-MSC对肝纤维化的疗效。结果：4周和10周进行治疗均可改善肝功能,减轻纤维化程度。结论：UC-MSC对CCl4诱导的肝纤维化具有一定的疗效。     

Flk1+间充质干细胞减轻四氯化碳导致的肝纤维化的研究

许多慢性肝脏疾病都会发生肝纤维化,但是目前尚缺乏对肝纤维化切实有效的治疗手段。实验发现,Flk1(fetal liver kinase)阳性间充质干细胞(MSC)能够减轻四氯化碳(CCl4)所致小鼠肝纤维化。取雄性BALB／c小鼠骨髓,分离培养Flk1^ MSC,用CCl4制作雌性小鼠肝纤维化模型,在CCl4损伤后立即或1周后经尾静脉注射Flk1^ MSC,2或5周后检测受体小鼠肝脏的纤维化程度和供体细胞的植入。结果发现,CCl4损伤后立即注射Flk1^ MSC,可以使肝脏损伤程度明显减轻,减少胶原沉积,使肝脏羟脯氨酸含量及血清纤维化指标显下降;而损伤1周后注射细胞则无明显变化。免疫荧光、PCR和荧光原位杂交方法证实,在受体肝脏中有供体细胞植入,呈上皮细胞形态,并表达白蛋白,但是数量很少。因此,Flk1^ MSC具有潜在的植入肝组织的能力,并可能启动肝组织的内源性修复,减轻CCl4导致的肝纤维化。     

Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIP

Chronic liver disease promotes hepatocellular injury involving apoptosis and triggers compensatory regeneration that leads to the activation of quiescent stellate cells in the liver. The deposition of extracellular matrix from activated myofibroblasts promotes hepatic fibrosis and the progression to cirrhosis with deleterious effects on liver physiology. The role of apoptosis signaling pathways in the development of fibrosis remains undefined. The aim of the current study was to determine the involvement of the caspase-8 homologue cellular FLICE-inhibitory protein (cFLIP) during the initiation and progression of fibrosis. Liver injury and fibrosis from carbon tetrachloride (CCl(4)) and thioacetamide (TAA) were examined in mice exhibiting a hepatocyte-specific deletion of cFLIP (flip(-/-)). Acute liver injury from CCl(4) and TAA were enhanced in flip(-/-) mice. This was accompanied by increased activation of caspase-3 and -9, pronounced phosphorylation of JNK, and decreased phosphorylation of Erk. Deletion of the cJun NH(2)-terminal kinase 2 (JNK2) in flip(-/-) mice protected from injury. Hepatic fibrosis was increased at baseline in 12-wk-old flip(-/-) mice, and progression of fibrosis from TAA was accelerated compared with the wild type. In conclusion, deletion of cFLIP in hepatocytes leads to increased fibrosis and accelerated fibrosis progression. This is accompanied by increased injury involving the activation of caspases and JNK2. Thus predisposition to liver injury involving increased hepatocellular apoptosis is a critical mediator of accelerated fibrogenesis, and prevention of liver injury will be a most important measure for patients with chronic liver disease.